The clinical trial conducted by Bispebjerg Hospital investigates the potential of IGF-I (mecasermin) to enhance collagen synthesis in patients with Ehlers-Danlos syndrome (EDS), a rare connective tissue disorder. Given the limited treatment options for EDS, a successful outcome could position mecasermin as a novel therapeutic approach, potentially capturing a niche market. The trial's completion in 2012 suggests that data may be available for further analysis, which could inform future development strategies. Competitive implications include the need to assess other therapies targeting collagen synthesis or connective tissue disorders, as well as the potential for partnerships or licensing opportunities based on trial outcomes.